Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations

Lung cancer with epidermal growth factor receptor (EGFR)-activating mutations responds favorably to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. However, 25% to 30% of patients with EGFR-activating mutations show intrinsic resistance, and the responders invariably acquire resistance...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2008-11, Vol.68 (22), p.9479-9487
Hauptverfasser:	Yano, Seiji, Wang, Wei, Li, Qi, Matsumoto, Kunio, Sakurama, Haruko, Nakamura, Takahiro, Ogino, Hirokazu, Kakiuchi, Soji, Hanibuchi, Masaki, Nishioka, Yasuhiko, Uehara, Hisanori, Mitsudomi, Tetsuya, Yatabe, Yasushi, Nakamura, Toshikazu, Sone, Saburo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Cell Line, Tumor Drug Resistance, Neoplasm Hepatocyte Growth Factor - pharmacology Humans Lung Neoplasms - drug therapy Mutation Phosphatidylinositol 3-Kinases - physiology Phosphorylation Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins - metabolism Proto-Oncogene Proteins c-akt - metabolism Proto-Oncogene Proteins c-met Quinazolines - pharmacology Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - physiology Receptor, ErbB-3 - metabolism Receptors, Growth Factor - genetics Receptors, Growth Factor - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!